Effective management of type 2 diabetes requires tight control of blood glucose levels to prevent long-term complications. Recently a number of new oral therapies have become available to help patients achieve this goal. This article provides information on how each agent works, how these different agents may be used, and the side-effects to look out for.
The prevalence of type 2 diabetes is rising and people are developing the condition at an earlier age. Type 2 diabetes becomes progressively more difficult to control over time, so many people need to start on insulin therapy as the pancreas is no longer able to meet the body's insulin requirements on its own. In this article,we look at the practical issues involved in helping a patient to start on insulin therapy for their diabetes.
The American Heart Association has published a scientific statement providing prescribers with a list of drugs that can cause or worsen heart failure. Heart failure patients are usually taking medications for multiple medical conditions with resulting risk for drug-drug or drug-condition interactions.
Aspirin is the most widely used long-term antiplatelet therapy, achieving benefits in patients with a range of cardiovascular conditions by blocking one of the blood clotting pathways. It is cheap and relatively safe, despite the possible risks of gastric irritation or bleeding. In this article, we explore what we know about aspirin, together with its pros and cons in patients with cardiovascular disease.
Patients with diabetes are at high risk of cardiovascular disease and aspirin is an important part of prevention strategies. Although it is effective and relatively well-tolerated, studies have shown that many patients with diabetes are not taking aspirin. In this article, we review why aspirin should be considered in patients with diabetes, the benefits it might achieve and areas where caution is required.
A number of drug classes are used in the treatment of patients with heart failure. This illustrated Back to Basics poster describes the various drugs and their mechanisms of action to give health care professionals and their patients a greater understanding of heart failure management and where sacubitril/valsartan fits into the picture.
This month’s Back to Basics feature is a patient information card that is included in the 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. The card can be folded into pocket size and is crucial both for the patient and for healthcare providers.
This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all undergo significant pathophysiological changes as HF progresses.